FR0014000MR3 - Common Stock

**ERF** gets a fundamental rating of **4** out of 10. The analysis compared the fundamentals against 15 industry peers in the **Life Sciences Tools & Services** industry. Both the profitability and the financial health of **ERF** get a neutral evaluation. Nothing too spectacular is happening here. **ERF** is not valued too expensively and it also shows a decent growth rate.

Each year in the past 5 years **ERF** had a positive operating cash flow.

Looking at the **Return On Assets**, with a value of **2.36%**, **ERF** is doing worse than **60.00%** of the companies in the same industry.

The **Return On Invested Capital** of **ERF** (**7.33%**) is better than **73.33%** of its industry peers.

Measured over the past 3 years, the **Average Return On Invested Capital** for **ERF** is above the industry average of **6.71%**.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 2.36% | ||

ROE | 5.05% | ||

ROIC | 7.33% |

ROA(3y)5.38%

ROA(5y)4.78%

ROE(3y)11.1%

ROE(5y)10.42%

ROIC(3y)10.55%

ROIC(5y)9.93%

The **Operating Margin** of **ERF** (**12.92%**) is worse than **66.67%** of its industry peers.

In the last couple of years the **Operating Margin** of **ERF** has remained more or less at the same level.

In the last couple of years the **Gross Margin** of **ERF** has grown nicely.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 12.92% | ||

PM (TTM) | 3.94% | ||

GM | 20.93% |

OM growth 3Y-11.78%

OM growth 5Y-1.27%

PM growth 3Y-24.89%

PM growth 5Y-3.22%

GM growth 3Y-6.94%

GM growth 5Y1.92%

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so **ERF** is still creating some value.

Compared to 5 years ago, **ERF** has more shares outstanding

Compared to 1 year ago, **ERF** has a worse debt to assets ratio.

The Debt to FCF ratio of **ERF** is **8.39**, which is on the high side as it means it would take **ERF**, **8.39** years of fcf income to pay off all of its debts.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.65 | ||

Debt/FCF | 8.39 | ||

Altman-Z | 2.52 |

ROIC/WACC0.82

WACC8.93%

A Quick Ratio of **1.38** indicates that **ERF** should not have too much problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.45 | ||

Quick Ratio | 1.38 |

The **Earnings Per Share** has been growing slightly by **6.31%** on average over the past years.

Looking at the last year, **ERF** shows a decrease in **Revenue**. The Revenue has decreased by **-2.94%** in the last year.

The **Revenue** has been growing by **11.49%** on average over the past years. This is quite good.

EPS 1Y (TTM)-56.01%

EPS 3Y-20.53%

EPS 5Y6.31%

EPS Q2Q%6.85%

Revenue 1Y (TTM)-2.94%

Revenue growth 3Y6.2%

Revenue growth 5Y11.49%

Sales Q2Q%0.14%

Based on estimates for the next years, **ERF** will show a quite strong growth in **Earnings Per Share**. The EPS will grow by **17.30%** on average per year.

EPS Next Y24.62%

EPS Next 2Y19.84%

EPS Next 3Y17.75%

EPS Next 5Y17.3%

Revenue Next Year7.97%

Revenue Next 2Y7.74%

Revenue Next 3Y7.56%

Revenue Next 5Y8.8%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

The **Price/Earnings** ratio is **41.28**, which means the current valuation is very expensive for **ERF**.

Compared to the rest of the industry, the **Price/Earnings** ratio of **ERF** is on the same level as its industry peers.

Based on the **Price/Forward Earnings** ratio, **ERF** is valued cheaper than 86.67% of the companies in the same industry.

When comparing the **Price/Forward Earnings** ratio of **ERF** to the average of the S&P500 Index (**20.38**), we can say **ERF** is valued inline with the index average.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 41.28 | ||

Fwd PE | 16.94 |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **ERF** indicates a rather cheap valuation: **ERF** is cheaper than 93.33% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 21.61 | ||

EV/EBITDA | 8.51 |

PEG (NY)1.68

PEG (5Y)6.54

EPS Next 2Y19.84%

EPS Next 3Y17.75%

With a **Dividend Yield** of **0.94**, **ERF** pays less dividend than the S&P500 average, which is at **2.32**.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 0.94% |

On average, the dividend of **ERF** grows each year by **37.65%**, which is quite nice.

Dividend Growth(5Y)37.65%

Div Incr Years0

Div Non Decr Years2

DP74.81%

EPS Next 2Y19.84%

EPS Next 3Y17.75%

**EUROFINS SCIENTIFIC**

EPA:ERF (8/9/2024, 7:00:00 PM)

**52.84**

**-0.22 (-0.41%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap10.11B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 0.94% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 41.28 | ||

Fwd PE | 16.94 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)1.68

PEG (5Y)6.54

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 2.36% | ||

ROE | 5.05% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 12.92% | ||

PM (TTM) | 3.94% | ||

GM | 20.93% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.6

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.65 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.45 | ||

Quick Ratio | 1.38 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-56.01%

EPS 3Y-20.53%

EPS 5Y

EPS Q2Q%

EPS Next Y24.62%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-2.94%

Revenue growth 3Y6.2%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y